Vaccine Stocks Slump as Novavax and Moderna Lead Sector Selloff

Key Facts

1Novavax stock dropped 12% to $11.23, leading the decline among vaccine developers.

2Moderna shares tumbled 10% while Pfizer remained steady during afternoon trading.

Novavax stock dropped 12% to $11.23 during afternoon trading, leading a sharp decline among vaccine developers. 247wallst.com reported that Moderna shares tumbled 10% while Pfizer remained relatively steady during the same session.

The sector is currently under heavy selling pressure, with smaller developers like Novavax taking the largest hits. Prior to the current move, NVAX closed at $12.82 on October 15, 2026. On the same date, MRNA closed at $236.5 and PFE closed at $29.44, highlighting a divergence in performance across the biotechnology group as market volatility impacts individual players differently.